India, April 9 -- Glenmark Pharmaceuticals on Thursday announced that it has received final approval from the US Food and Drug Administration (USFDA) for its generic progesterone vaginal inserts used in fertility treatments.
The approval covers the 100 mg strength of the product, the company said in a regulatory filing.
According to the USFDA, the product is bioequivalent and therapeutically equivalent to the reference listed drug, Endometrin vaginal inserts, 100 mg, developed by Ferring Pharmaceuticals.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....